Ukrainian chemistry SME specializing in cage metal complex probes and fluorescent dyes for protein sensing and anticancer drug imaging.
Innovation Development Center ABN is a Ukrainian research-chemistry SME specializing in the design, synthesis, and spectroscopic characterization of metal complex-based optical probes and fluorescent dyes for biomedical applications. Their core expertise lies in clathrochelate chemistry — a narrow but technically demanding field of cage metal complexes — which they apply to build sensing tools that detect proteins and visualize drugs inside living cells and organisms. In practice, they contribute synthetic chemistry capacity and optical analysis skills (fluorescence, circular dichroism, NMR, IR) to international research consortia via MSCA-RISE staff exchange programs. Their work sits at the intersection of inorganic coordination chemistry and translational biomedical science, feeding into anticancer drug research and diagnostics development.
CLATHROPROBES (2018–2023) was built entirely around their ability to synthesize cage metal complexes and characterize them via chiroptical, optical, and magnetic methods for protein sensing.
NoBiasFluors (2020–2024) extended their dye synthesis expertise toward red fluorescent markers designed for in cellulo and in vivo optical imaging of anticancer drugs.
Both projects rely on multi-technique optical and spectroscopic analysis as the primary readout method, indicating sustained analytical capability across their full H2020 timeline.
NoBiasFluors introduced conjugation of fluorescent dyes to peptides, nucleopeptides, and lectins — a newer capability layer built on top of their core synthesis skills.
Their early work (2018) centered on inorganic coordination chemistry: clathrochelates, cage metal complexes, and their interaction with serum proteins like albumins — probed through chiroptical methods such as circular dichroism. By 2020 the focus had moved decisively toward organic fluorescent dyes and their conjugation to biologically active molecules (peptides, nucleopeptides, lectins) for tracking anticancer drugs inside live cells and whole organisms. The trajectory is a clear shift from fundamental inorganic probe chemistry toward applied translational biomedical imaging, with the underlying spectroscopic and synthetic skills carrying over but being redirected at living systems rather than isolated proteins.
They are moving from fundamental coordination chemistry toward applied bioimaging tools for drug research, making them an increasingly relevant partner for consortia targeting cancer diagnostics, optical biosensing, or theranostics.
They have participated exclusively as consortium members, never as coordinator, across both projects — indicating they function as a specialist technical contributor rather than a project driver. Both projects ran under MSCA-RISE, a staff-exchange scheme, which means their collaboration model is built around researcher mobility and shared lab access rather than subcontracting or deliverable-based partnerships. With 12 distinct partners across 9 countries from just two projects, they engage in mid-sized, internationally diverse consortia typical of the RISE program.
They have built a network of 12 unique consortium partners spanning 9 countries through only two projects — a relatively broad reach for a small SME, explained by the multi-partner structure of MSCA-RISE exchanges. No geographic clustering is visible in the data, suggesting an open, opportunity-driven approach to international partnerships rather than reliance on established bilateral ties.
This organization occupies a genuinely rare niche: a private-sector entity (not a university or institute) with demonstrated expertise in clathrochelate chemistry, a highly specialized subfield of cage metal complex synthesis with few active research groups globally. For a consortium needing synthetic chemistry capacity in Ukraine combined with spectroscopic characterization and growing bioimaging credentials, they offer skills that are difficult to source from standard academic partners. Their SME status also makes them eligible for specific funding instruments that pure research institutions cannot access.
